Reply to V. Amoroso et al
- PMID: 28113028
- DOI: 10.1200/JCO.2017.71.3875
Reply to V. Amoroso et al
Comment on
-
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.J Clin Oncol. 2016 Nov 10;34(32):3906-3913. doi: 10.1200/JCO.2016.68.0702. Epub 2016 Sep 30. J Clin Oncol. 2016. PMID: 27621394 Free PMC article. Clinical Trial.
-
When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?J Clin Oncol. 2017 May 1;35(13):1487-1488. doi: 10.1200/JCO.2016.71.0103. Epub 2017 Jan 23. J Clin Oncol. 2017. PMID: 28113025 No abstract available.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical